Investor News

1 - 10

11 - 20

21 - 30

31 - 40

41 - 50

May 15, 2019

Not intended for U.S. and UK Media - Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019

New data for larotrectinib show overall response rates of 94% in children and 76% in adults with TRK fusion cancer; clinical benefit demonstrated in patients with primary central nervous system tumors and brain metastases

May 13, 2019

Bayer statement on jury's decision in California State Glyphosate Trial

May 13, 2019

Beiersdorf to acquire iconic Coppertone™ brand from Bayer

May 13, 2019

Not intended for U.S. and UK Media - 2019 American Society of Clinical Oncology (ASCO) Annual Meeting:

Bayer to present new data at ASCO 2019 highlighting commitment to evolve cancer treatment paradigm

April 29, 2019

Not intended for U.S. and UK Media

U.S. FDA accepts new drug application and grants priority review for darolutamide

April 29, 2019

Not intended for U.S. and UK Media

Study reaffirms safety and efficacy profile of Xarelto™ for the prevention of stroke in patients with atrial fibrillation

April 27, 2019

After Annual Stockholders' Meeting votes to not ratify Board of Management's actions:

Bayer's Supervisory Board unanimously stands behind Board of Management

April 26, 2019

CEO Werner Baumann at the Annual Stockholders' Meeting of Bayer AG:

"We made great progress - both operationally and strategically"

April 25, 2019

First quarter of 2019:

Bayer: strong operational start to the year

March 27, 2019

Bayer statement on jury's decision in phase two of California glyphosate trial

1 - 10

11 - 20

21 - 30

31 - 40

41 - 50

Previous News can be found in the Archive

Services

Current Event

December 10, 2019

Investor Conference Call: Bayer 2030 Sustainable Development Objectives

Overview

Current Links

IR News Archive Overview

Download Acrobat Reader

Email Newsletter

RSS Newsfeed

Last updated: February 15, 2019

Investor News

Services

Download Center

Current Event

Current Links